Clinical Trials Logo

Clinical Trial Summary

To evaluate if a flexible dose escalation of lacosamide, up to the maximum approved dose of 400 mg/day, or to a clinically effective lower dose for an individual patient, improves the tolerability and safety of lacosamide (200 mg to 400 mg/d) as add-on treatment for patients with partial onset epilepsy.

Explanation of acronym: SELF = Safety Efficacy Lacosamide Flexibility


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01235403
Study type Interventional
Source UCB Pharma
Contact
Status Completed
Phase Phase 4
Start date June 2010
Completion date December 2011

See also
  Status Clinical Trial Phase
Completed NCT00522275 - Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures Phase 3
Completed NCT00955357 - Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures Phase 4
Completed NCT00552305 - To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures Phase 2
Completed NCT00655551 - Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures Phase 3
Completed NCT00655486 - Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures Phase 3